Related Experiment Video
Updated: Feb 1, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy
Giulia Notini1,2,3,4, Giampaolo Bianchini1,2, José Manuel Perez-Garcia3,4
1Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Abstract:
Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.
Insights
Antibody-drug conjugates show promise for advanced breast cancer across all subtypes. Challenges remain in treatment sequencing, trial design, tolerability, and global development.
Area of Science:
- Oncology
- Pharmacology
Background:
- Antibody-drug conjugates (ADCs) are emerging as a significant therapeutic class in oncology.
- ADCs demonstrate broad efficacy in advanced breast cancer, irrespective of subtype.
Purpose of the Study:
- To review the current landscape and challenges of antibody-drug conjugates in advanced breast cancer treatment.
Main Methods:
- Literature review of recent clinical trials and research publications on ADCs in breast cancer.
- Analysis of current treatment guidelines and expert opinions.
Main Results:
- ADCs show efficacy across estrogen receptor-positive, HER2-positive, and triple-negative breast cancer subtypes.
- Key challenges include optimizing treatment sequencing, ethical clinical trial design, managing drug toxicity, and overcoming limitations of single-country studies.
Conclusions:
- While ADCs represent a major advancement in breast cancer therapy, strategic planning is crucial for their effective and equitable implementation.
- Addressing challenges in sequencing, trial design, tolerability, and global collaboration is essential for maximizing ADC benefits.
More Related Videos
Related Concept Videos
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Conjugated Proteins
Conjugation
Clinically Relevant Drug Product Specifications: Methods of Establishment
Mechanism of Conjugation
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

